Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP7 | P55210 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | BRD9 | Q9H8M2 | 1/20 | 0.39 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23828427 | 0.88 | BRD9 (0.51) | KDM4EALDH1A1HPGDHSD17B10MEN1 | |
| SCHEMBL23828381 | 0.87 | ADORA3 (0.46) | KDM4EALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL23828484 | 0.85 | ADORA3 (0.57) | KDM4EALDH1A1HPGDCASP1CASP7 | |
| SCHEMBL23828574 | 0.85 | PTGS2 (0.41) | KDM4EALDH1A1BRD9GSK3BDYRK1A | |
| SCHEMBL23828333 | 0.85 | BRD9 (0.38) | BRD9ADORA2AADORA2BGSK3BDYRK1A | |
| SCHEMBL23828605 | 0.83 | POLB (0.41) | KDM4EALDH1A1HPGDTP53BRD9 | |
| SCHEMBL23828423 | 0.82 | ADORA3 (0.54) | HPGDADORA3GSK3B | |
| SCHEMBL23828440 | 0.81 | BRD9 (0.42) | KDM4EALDH1A1HPGDHSD17B10ADORA3 | |
| SCHEMBL23828576 | 0.71 | HPGD (0.52) | KDM4EALDH1A1HPGDHSD17B10ADORA3 | |
| SCHEMBL2970159 | 0.70 | ATR (0.40) | CTSLADORA3TP53GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS, INC. (US) | 2025-04-01 | — | — | US | claimed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | claimed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | claimed |
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS, INC. (US) | 2025-04-01 | — | — | US | disclosed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2023-11-30 | — | — | US | disclosed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | EXELIXIS INC. (US) | 2023-08-08 | — | — | US | disclosed |
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2021-09-23 | — | — | US | disclosed |
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | EXELIXIS, INC. | 2021-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210292332-A1 | Heterocyclic Adenosine Receptor Antagonists | ADORA2A, ADORA1, ADORA3 | CTSL 3245/4885KDM4E 4514/4885ALDH1A1 789/4885 |
| US-20230382917-A1 | Heterocyclic Adenosine Receptor Antagonists | ADORA2A, ADORA1, ADORA3 | CTSL 3245/4885KDM4E 4514/4885ALDH1A1 789/4885 |
| US-11718622-B2 | Heterocyclic adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | CTSL 3245/4885KDM4E 4514/4885ALDH1A1 789/4885 |
| US-12264161-B2 | Heterocyclic adenosine receptor antagonists | ADORA2A, ADORA1, ADORA3 | CTSL 3245/4885KDM4E 4514/4885ALDH1A1 789/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.